Loading…
Loading…
EQUITY / NASDAQ · XNCM
Regencell Bioscience Holdings Limited
No accepted understanding yet. Follow this company to establish research where evidence supports it.
Open research workspace →07/01/2024 – 06/30/2025 · USD · Units
Reported figures establish facts for this period; they do not by themselves establish a profitability trend.
Open report ↗6.82 USD
Observed: 10/02/2026 · tickerlayer · Historical end-of-day close
Powered by TickerLayer
10/02/2026 · 6.82 USD · Volume 429,449
250 actual observations · Latest bar: 2026-10-02 · Market data is indicative; provider terms apply.
3 available financial reports
Research reports →SEC FINANCIAL REPORTS
07/01/2024 – 06/30/2025 · Units
| Metric | 2025 / Year end | 2024 / Year end | Change |
|---|---|---|---|
| Operating profit | -3,769,985 USD | -4,736,726 USD | — |
| Net income | -3,584,213 USD | -4,301,837 USD | — |
| Operating cash flow | -3,113,576 USD | -4,001,687 USD | — |
| Total liabilities | 895,308 USD | 219,512 USD | +307.86% |
| Total equity | 4,860,274 USD | 8,218,699 USD | -40.86% |
Changes are calculated only for matching period length, consolidation, currency, and scale. Percentages are not shown for zero or negative baselines.
Each column uses its report's scale. Check column headers before comparing different consolidation scopes and scales.
| Financial metric | 2025 / Year end07/01/2024 – 06/30/2025ConsolidatedUnits · USD | 2024 / Year end07/01/2023 – 06/30/2024ConsolidatedUnits · USD | 2023 / Year end07/01/2022 – 06/30/2023ConsolidatedUnits · USD |
|---|---|---|---|
| Capital expendituresCash flow statement | 152,689 USD | 5,376 USD | 27,392 USD |
| Investing cash flowCash flow statement | 2,686,216 USD | 5,242,624 USD | 58,978 USD |
| Net incomeIncome statement | -3,584,213 USD | -4,301,837 USD | -5,871,130 USD |
| Operating cash flowCash flow statement | -3,113,576 USD | -4,001,687 USD | -4,962,949 USD |
| Operating profitIncome statement | -3,769,985 USD | -4,736,726 USD | -6,273,671 USD |
| Total assetsBalance sheet | 5,755,582 USD | 8,438,211 USD | — |
| Total equityBalance sheet | 4,860,274 USD | 8,218,699 USD | 11,989,435 USD |
| Total liabilitiesBalance sheet | 895,308 USD | 219,512 USD | — |
| Financing cash flowCash flow statement | — | 102,282 USD | 134,913 USD |
| Report source | Open report ↗ Published: 10/31/2025 | Open report ↗ Published: 10/31/2025 | Open report ↗ Published: 10/31/2025 |
The latest available source version is shown for each period. Previous versions and correction relationships are not shown in this view.